TY  - JOUR
AU  - Palazon-Carrion, Natalia
AU  - Martin-Garcia-Sancho, Alejandro
AU  - Nogales-Fernandez, Esteban
AU  - Jimenez-Cortegana, Carlos
AU  - Carnicero-Gonzalez, Fernando
AU  - Rios-Herranz, Eduardo
AU  - de-la Cruz-Vicente, Fatima
AU  - Rodriguez-Garcia, Guillermo
AU  - Fernandez-Alvarez, Ruben
AU  - Martinez-Banaclocha, Natividad
AU  - Guma-Padro, Josep
AU  - Gomez-Codina, Jose
AU  - Salar-Silvestre, Antonio
AU  - Rodriguez-Abreu, Delvys
AU  - Galvez-Carvajal, Laura
AU  - Labrador, Jorge
AU  - Guirado-Risueño, Maria
AU  - Garcia-Dominguez, Daniel J
AU  - Hontecillas-Prieto, Lourdes
AU  - Espejo-Garcia, Pablo
AU  - Fernandez-Roman, Isabel
AU  - Provencio-Pulla, Mariano
AU  - Sanchez-Beato, Margarita
AU  - Navarro, Marta
AU  - Marylene, Lejeune
AU  - Alvaro-Naranjo, Tomas
AU  - Casanova-Espinosa, Maria
AU  - Sanchez-Margalet, Victor
AU  - Rueda-Dominguez, Antonio
AU  - de-la-Cruz-Merino, Luis
PY  - 2022
DO  - 10.1158/1078-0432.CCR-22-0588
UR  - http://hdl.handle.net/10668/20187
T2  - Clinical cancer research : an official journal of the American Association for Cancer Research
AB  - New therapeutic options are needed in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide-based schedules can reverse rituximab refractoriness in lymphoma. In the phase II R2-GDP trial, 78 patients unsuitable for autologous...
LA  - en
PB  - American Association for Cancer Research
KW  - Recurrence
KW  - Drug Resistance, Neoplasm
KW  - Drug Therapy, Combination
KW  - Progression-Free Survival
KW  - Overall Survival
KW  - Tumor Biomarkers
KW  - Adverse Events
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Biomarkers
KW  - Humans
KW  - Lenalidomide
KW  - Lymphoma, Large B-Cell, Diffuse
KW  - Lymphoma, Non-Hodgkin
KW  - Neoplasm Recurrence, Local
KW  - Rituximab
KW  - Treatment Outcome
TI  - Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
TY  - research article
VL  - 28
ER  -